Canlyniadau Chwilio - Plummer, Ruth

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? gan Plummer, Ruth

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Cancer immunotherapy and its potential cardiac complications gan Findlay, Simon G, Plummer, Ruth, Plummer, Chris

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Tremelimumab-Induced Graves Hyperthyroidism gan Gan, Earn H., Mitchell, Anna L., Plummer, Ruth, Pearce, Simon, Perros, Petros

Cael y testun llawn Cael y testun llawn Cael y testun llawn

mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition gan Massey, Andrew J., Stephens, Peter, Rawlinson, Rebecca, McGurk, Lauren, Plummer, Ruth, Curtin, Nicola J.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors gan Plummer, Ruth, Stephens, Peter, Aissat-Daudigny, Louiza, Cambois, Anne, Moachon, Gilbert, Brown, Peter D., Campone, Mario

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Mechanisms of Chemoresistance in Malignant Glioma gan Sarkaria, Jann N., Kitange, Gaspar J., James, C. David, Plummer, Ruth, Calvert, Hilary, Weller, Michael, Wick, Wolfgang

Cael y testun llawn Cael y testun llawn Cael y testun llawn

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours gan Ameratunga, Malaka, Braña, Irene, Bono, Petri, Postel-Vinay, Sophie, Plummer, Ruth, Aspegren, John, Korjamo, Timo, Snapir, Amir, de Bono, Johann S

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours:... gan Cranston, Amy, Stocken, Deborah D., Stamp, Elaine, Roblin, David, Hamlin, Julia, Langtry, James, Plummer, Ruth, Ashworth, Alan, Burn, John, Rajan, Neil

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study gan Brown, Jennifer, Plummer, Ruth, Bauer, Todd M., Anthony, Stephen, Sarantopoulos, John, De Vos, Filip, White, Mike, Schupp, Marco, Ou, Ying, Vaishampayan, Ulka

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours gan Shapiro, Geoffrey I., Wesolowski, Robert, Devoe, Craig, Lord, Simon, Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth, Yap, Timothy A.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours gan Middleton, Mark R., Dean, Emma, Evans, Thomas R. J., Shapiro, Geoffrey I., Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer gan Shaheen, Fadhel S., Znojek, Pawel, Fisher, Ann, Webster, Martin, Plummer, Ruth, Gaughan, Luke, Smith, Graeme C. M., Leung, Hing Y., Curtin, Nicola J., Robson, Craig N.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors gan Plummer, Ruth, Madi, Ayman, Jeffels, Melinda, Richly, Heike, Nokay, Bahar, Rubin, Stephen, Ball, Howard A., Weller, Steve, Botbyl, Jeffrey, Gibson, Diana M., Scheulen, Max E.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965 gan McNeillis, Rosie, Greystoke, Alastair, Walton, Jon, Bacon, Chris, Keun, Hector, Siskos, Alexandros, Petrides, George, Leech, Nicola, Jenkinson, Fiona, Bowron, Ann, Halford, Sarah, Plummer, Ruth

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965 gan McNeillis, Rosie, Greystoke, Alastair, Walton, Jon, Bacon, Chris, Keun, Hector, Siskos, Alexandros, Petrides, George, Leech, Nicola, Jenkinson, Fiona, Bowron, Ann, Halford, Sarah, Plummer, Ruth

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study proto... gan Menne, Tobias, Slade, Daniel, Savage, Joshua, Johnson, Sarah, Irving, Julie, Kearns, Pamela, Plummer, Ruth, Shenton, Geoff, Veal, Gareth J, Vormoor, Britta, Vormoor, Josef, Billingham, Lucinda

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine gan Twelves, Chris, Anthoney, Alan, Savulsky, Claudio I., Guo, Matthew, Reyderman, Larisa, Cresti, Nicola, Semiglazov, Vladimir, Timcheva, Constanta, Zubairi, Ishtiaq, Morrison, Rosemary, Plummer, Ruth, Evans, T. R. Jeffry

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours gan Wilson, Richard H, Evans, TR Jeffry, Middleton, Mark R, Molife, L Rhoda, Spicer, James, Dieras, Veronique, Roxburgh, Patricia, Giordano, Heidi, Jaw-Tsai, Sarah, Goble, Sandra, Plummer, Ruth

Cael y testun llawn Cael y testun llawn Cael y testun llawn

SARS-CoV-2 vaccination and phase 1 cancer clinical trials gan Yap, Timothy A, Siu, Lillian L, Calvo, Emiliano, Lolkema, Martijn P, LoRusso, Patricia M, Soria, Jean-Charles, Plummer, Ruth, de Bono, Johann S, Tabernero, Josep, Banerji, Udai

Cael y testun llawn Cael y testun llawn Cael y testun llawn

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor gan Plummer, Ruth, Dua, Divyanshu, Cresti, Nicola, Drew, Yvette, Stephens, Peter, Foegh, Marie, Knudsen, Steen, Sachdev, Pallavi, Mistry, Bipin M., Dixit, Vaishali, McGonigle, Sharon, Hall, Nancy, Matijevic, Mark, McGrath, Shannon, Sarker, Debashis

Cael y testun llawn Cael y testun llawn Cael y testun llawn